Two Stage Screening for Alzheimer's Disease Clinical Trial Recrutiment Enrichment: Cognivue Clarity and Plasma pTau217

Cognivue Clarity, a 10-minute computerized battery, can detect individuals with cognitive impairment and with the CARM can identify individuals likely to have amyloid positivity. To further increase the efficiency and cost-effectiveness of cognitive screening, a staged screening approach likely makes the most sense. Cognivue Clarity global scores establish whether there is cognitive impairment, and in the same sitting CARM predicts the likelihood of amyloid. This could be followed by measuring a readily accessible AD biomarker such as plasma pTau217. Such a strategy would increase the likelihood of identifying early AD for treatment or trial enrollment, avoiding the cost of expensive PET scans in a time- and cost-effective fashion.